Cutaneous lupus erythematosus Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo The

Cutaneous lupus erythematosus therapies such as Litifilimab, Daxdilimab, and others are expected to boost the Cutaneous lupus erythematosus Market in the upcoming years.

DelveInsight has launched a new report on "Cutaneous lupus erythematosus - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cutaneous lupus erythematosus, historical and forecasted epidemiology as well as the Cutaneous lupus erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover more about the cutaneous lupus erythematosus disease, diagnosis, treatment options @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Cutaneous lupus erythematosus Market Report:

The Cutaneous Lupus Erythematosus (CLE) market in the 7MM was valued at approximately USD 500 million in 2023.
Cutaneous lupus erythematosus, a chronic autoimmune disease affecting the skin, represents an estimated 10% of all lupus cases. The United States also leads in the number of diagnosed prevalent cases, with approximately 500,000 cases, followed by the EU4, UK, and Japan. The condition is more common in females (~64%) than in males (~36%) among diagnosed patients.
Around 70% of diagnosed patients receive treatment, which is typically a combination of topical and systemic therapies based on the disease's severity. More than 30% of cases are moderate-to-severe, requiring biologics and systemic immunomodulators in addition to standard treatments. Currently, the FDA has approved only two medications for CLE: hydroxychloroquine and glucocorticoids.
Emerging drug classes, such as BDCA2 protein inhibitors, dendritic cell inhibitors, and TYK2 kinase inhibitors, are expected to expand the treatment options for CLE. Biogen's litifilimab and Bristol Myers Squibb's deucravacitinib are anticipated to be the leading drugs in the market during the 2024-2034 forecast period, each expected to account for around 25% of the total market sales.
Other companies, including Horizon Therapeutics, Gilead Sciences, and Merck KGaA, are also developing treatments for CLE. In January 2023, Horizon Therapeutics announced the enrollment of the first patient in a Phase II trial for moderate-to-severe primary discoid lupus erythematosus.
In 2023, the total number of diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE) across the 7MM was around 800,000, and this figure is expected to rise over the forecast period. Studies indicate that roughly two-thirds of individuals with lupus will experience some form of skin involvement, and each year, about 2% of patients with systemic lupus erythematosus (SLE) go on to develop CLE.
In April 2024, results published by the Lupus Research Alliance reported that deucravacitinib, a TYK2 inhibitor, significantly improved CLE symptoms.
A Medscape article from April 2024 presented global survey data on how CLE affects patients' mental health, social life, and financial stability.
In Ocotber 2023, Biogen released Phase 2 trial results in October 2023 showing that litifilimab (BIIB059) significantly reduced CLE disease activity.
Key Cutaneous lupus erythematosus companies such as Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others are evaluating new drugs for Cutaneous lupus erythematosus to improve the treatment landscape.
Promising Cutaneous lupus erythematosus therapies include Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others.
Key benefits of the Cutaneous lupus erythematosus market report:
Cutaneous lupus erythematosus market report covers a descriptive overview and comprehensive insight of the Cutaneous lupus erythematosus Epidemiology and Cutaneous lupus erythematosus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Cutaneous lupus erythematosus market report provides insights on the current and emerging therapies.
Cutaneous lupus erythematosus market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Cutaneous lupus erythematosus market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cutaneous lupus erythematosus market.

Got queries? Click here to know more about the Cutaneous lupus erythematosus Market Landscape https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cutaneous lupus erythematosus Overview

Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune disorder that primarily affects the skin and is part of the lupus erythematosus family, where the symptoms are confined to the skin. Lupus Erythematosus (LE) is a broader, chronic autoimmune disease that impacts multiple organs and systems with a wide range of symptoms. It is divided into three main forms: acute cutaneous lupus erythematosus (ACLE), subacute CLE, and chronic cutaneous lupus erythematosus (CCLE). CCLE includes conditions such as discoid LE (DLE), LE profundus (LEP), chilblain LE (CHLE), and LE tumidus (LET). Diagnosing Cutaneous Lupus Erythematosus involves classifying the specific subtype through a combination of physical examination, laboratory tests, histology, antibody serology, and sometimes direct immunofluorescence, while ruling out the presence of systemic disease.

Cutaneous lupus erythematosus Market Outlook

The dynamics of the Cutaneous lupus erythematosus market is anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others during the forecast period 2020-2034.

Explore how the cutaneous lupus erythematosus market is rising in the upcoming years @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cutaneous lupus erythematosus Emerging Drugs
Litifilimab: Biogen
Daxdilimab: Horizon Therapeutics/ Amgen

Scope of the Cutaneous lupus erythematosus Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cutaneous lupus erythematosus Companies: Biogen, Horizon Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Daiichi Sankyo, Inc., EMD Serono, Hoth Therapeutics, Zylo Therapeutics, Sanofi, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, Horizon Therapeutics, and others
Key Cutaneous lupus erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others
Cutaneous lupus erythematosus Therapeutic Assessment: Cutaneous lupus erythematosus current marketed and Cutaneous lupus erythematosus emerging therapies
Cutaneous lupus erythematosus Market Dynamics: Cutaneous lupus erythematosus market drivers and Cutaneous lupus erythematosus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Cutaneous lupus erythematosus Unmet Needs, KOL's views, Analyst's views, Cutaneous lupus erythematosus Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cutaneous lupus erythematosus Patient Share (%) Overview at a Glance
5. Cutaneous lupus erythematosus Market Overview at a Glance
6. Cutaneous lupus erythematosus Disease Background and Overview
7. Cutaneous lupus erythematosus Epidemiology and Patient Population
8. Country-Specific Patient Population of Cutaneous lupus erythematosus
9. Cutaneous lupus erythematosus Current Treatment and Medical Practices
10. Unmet Needs
11. Cutaneous lupus erythematosus Emerging Therapies
12. Cutaneous lupus erythematosus Market Outlook
13. Country-Wise Cutaneous lupus erythematosus Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cutaneous lupus erythematosus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Cutaneous lupus erythematosus Market Outlook 2034 https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Cutaneous lupus erythematosus Pipeline Insights, DelveInsight

"Cutaneous lupus erythematosus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cutaneous lupus erythematosus market. A detailed picture of the Cutaneous lupus erythematosus pipeline landscape is provided, which includes the disease overview and Cutaneous lupus erythematosus treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.